

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Keisha Douglas

Timestamp: Fri Aug 31 08:59:18 EDT 2007

=====

Application No: 10528989 Version No: 2.0

Input Set:

Output Set:

Started: 2007-08-20 09:26:07.159
Finished: 2007-08-20 09:26:13.658
Elapsed: 0 hr(s) 0 min(s) 6 sec(s) 499 ms
Total Warnings: 27
Total Errors: 0
No. of SeqIDs Defined: 27
Actual SeqID Count: 27

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)

Input Set:

Output Set:

Started: 2007-08-20 09:26:07.159
Finished: 2007-08-20 09:26:13.658
Elapsed: 0 hr(s) 0 min(s) 6 sec(s) 499 ms
Total Warnings: 27
Total Errors: 0
No. of SeqIDs Defined: 27
Actual SeqID Count: 27

Error code	Error Description
	This error has occurred more than 20 times, will not be displayed

SEQUENCE LISTING

<110> VALTANEN, Heli et al.
<120> METHOD FOR DESIGNING PEPTIDES
<130> 0933-0238PUS1
<140> 10528989
<141> 2005-10-25

<150> PCT/FI2003/000705
<151> 2003-09-29

<160> 27

<170> PatentIn version 3.3

<210> 1
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic intein Fwd SapI primer

<400> 1
cctttctgct cttccaaacgc cgacggggct 30

<210> 2
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic intein Rev PstI primer
<400> 2
actttcaacc tgcagttacc cagcgcccc 30

<210> 3
<211> 59
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic oligonucleotide encoding SEQ ID NO: 10

<400> 3
ggtgtgtgctc ttccaactgt acgaccatt ggggatttac tttatgttaa ctgcaggcg 59

<210> 4
<211> 15

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer used to convert SEQ ID NO: 3 to double-stranded form

<400> 4
cgccctgcagt taaca 15

<210> 5
<211> 75
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic degenerate oligonucleotide used in the cloning of the intein-peptide fusions

<400> 5
ggtggttgct cttccaaacgg ccgcccvavva vtatvavggc tgtaccaccc atttacttta 60
tgttaactgc aggcg 75

<210> 6
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Transposon specific primer

<400> 6
atcagcggcc gcgatcc 17

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Transposon specific primer

<400> 7
ttattcggtc gaaaaggatc c 21

<210> 8
<211> 4
<212> PRT
<213> Unknown

<220>
<223> Peptide derived from phage

<400> 8

Ala Asp Gly Ala

1

<210> 9

<211> 4

<212> PRT

<213> Unknown

<220>

<223> Peptide derived from phage

<400> 9

Gly Ala Ala Gly

1

<210> 10

<211> 10

<212> PRT

<213> Unknown

<220>

<223> CTT-peptide recombinantly prepared by the intein system

<400> 10

Cys Thr Thr His Trp Gly Phe Thr Leu Cys

1

5

10

<210> 11

<211> 10

<212> PRT

<213> Unknown

<220>

<223> Non-cyclic synthetic control peptide

<400> 11

Ser Thr Thr His Trp Gly Phe Thr Leu Ser

1

5

10

<210> 12

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Ala-substitution at residue 2 of the
CTT-peptide (SEQ ID: 10)

<400> 12

Cys Ala Thr His Trp Gly Phe Thr Leu Cys

1

5

10

<210> 13
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 3 of the CTT-peptide (SEQ ID: 10)

<400> 13
Cys Thr Ala His Trp Gly Phe Thr Leu Cys
1 5 10

<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 4 of the CTT-peptide (SEQ ID: 10)

<400> 14
Cys Thr Thr Ala Trp Gly Phe Thr Leu Cys
1 5 10

<210> 15
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 5 of the CTT-peptide (SEQ ID: 10)

<400> 15
Cys Thr Thr His Ala Gly Phe Thr Leu Cys
1 5 10

<210> 16
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 6 of the CTT-peptide (SEQ ID: 10)

<400> 16
Cys Thr Thr His Trp Ala Phe Thr Leu Cys
1 5 10

<210> 17

<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 7 of the CTT-peptide (SEQ ID: 10)

<400> 17
Cys Thr Thr His Trp Gly Ala Thr Leu Cys
1 5 10

<210> 18
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 8 of a mutated CTT-peptide (SEQ ID: 10)

<400> 18
Cys Thr Thr His Trp Gly Phe Ala Leu
1 5

<210> 19
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 8 of the CTT-peptide (SEQ ID: 10)

<400> 19
Cys Thr Thr His Trp Gly Phe Ala Leu Cys
1 5 10

<210> 20
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
CTT-peptide with a tryptophan analogue at position 5

<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa at position 5 is 5-OH-Trp, 5-F-Trp or 6-F-Trp

<400> 20

Cys Thr Thr His Xaa Gly Phe Thr Leu Cys
1 5 10

<210> 21
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Control sequence

<400> 21
Cys Glu Arg Gly Gly Leu Glu Thr Ser Cys
1 5 10

<210> 22
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Control sequence

<400> 22
Cys Pro Cys Phe Leu Leu Gly Cys Cys
1 5

<210> 23
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
CTT-peptide with additional hydrophilic amino acids at positions 2-6 and
Gly at positions 1 and 7 which is aliphatic

<220>
<221> misc_feature
<222> (3)...(4)
<223> Xaa at positions 3 and 4 is any hydrophilic amino acid

<220>
<221> misc_feature
<222> (6)...(6)
<223> Xaa at position 6 is any hydrophilic amino acid

<400> 23
Gly Arg Xaa Xaa Tyr Xaa Gly Cys Thr Thr His Trp Gly Phe Thr Leu
1 5 10 15
Cys

<210> 24
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
 CTT-peptide of SEQ ID NO: 10 with additional hydrophilic amino acids at
 positions 2-6 and Gly at positions 1 and 7 which is aliphatic

<400> 24
Gly Arg Glu Asn Tyr His Gly Cys Thr Thr His Trp Gly Phe Thr Leu
 1 5 10 15

Cys

<210> 25
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide derived from phage

<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa can be any naturally occurring amino acid and (X)n may be present or
 absent. Xaa at position 5 is the peptide insertion point.

<400> 25
Ala Asp Gly Ala Xaa Gly Ala Ala Gly
 1 5

<210> 26
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MMP-2 specific fluorescent peptide
 substrate

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is MCA

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is Nva

<220>
<221> MISC_FEATURE
<222> (6)...(6)
<223> Xaa is Dpa

<400> 26

Xaa Pro Leu Ala Xaa Xaa Ala Arg
1 5

<210> 27
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: recombinant peptide prepared by the
intein system

<400> 27

Cys Thr Thr His Trp Gly Phe Thr Ala Cys
1 5 10